← Back to Clinical Trials
Recruiting NCT06715215

NCT06715215 Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06715215
Status Recruiting
Phase
Sponsor Sohag University
Condition Immune Thrombocytopenia
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-11-15
Primary Completion 2025-12-30

Trial Parameters

Condition Immune Thrombocytopenia
Sponsor Sohag University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 1 Year
Max Age 50 Years
Start Date 2024-11-15
Completion 2025-12-30
Interventions
Acute phase proteins

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in thrombocytopenia Acute phase proteins (APP) are inflammation markers that exhibit significant changes in serum concentration during inflammation. These are also important mediators produced in the liver during acute and chronic inflammatory states. Acute phase reactants can be classified as positive or negative, depending on their serum concentrations during inflammation. Positive acute phase reactants are upregulated, and their concentrations increase during inflammation. Negative acute phase reactants are downregulated, and their concentrations decrease during inflammation. Positive acute phase proteins include procalcitonin, C-reactive protein, ferritin, fibrinogen, hepcidin, and serum amyloid A. Negative acute phase reactants include albumin, prealbumin, transferrin, retinol-binding protein, and antithrombin CRP is now well established as a major acute phase protein and is used in daily clinical practice as a sensitive biomarker for infection and inflammation, with its level increasing from \<0.05 to \>500 mg/L after acute infections. CRP is produced by hepatocytes, in response to inflammatory cytokines such as interleukin (IL)-6 and IL-1, with serum concentrations rising to \>5 mg/L after 6 hours and peaking after ∼48 hours. In healthy young adult volunteer blood donors, the median concentration of CRP was found to be ∼0.8 mg/L CRP levels are useful as a clinical diagnostic tool for infection, and it is a common knowledge that ITP is triggered by viral infection that precedes the clinical picture of ITP by a few days to a few weeks Procalcitonin (PCT) is used as a reliable inflammatory biomarker with high sensitivity and specificity ferritin was confirmed as an inflammation and infection biomarker in the diagnosis of viral and bacterial infections.

Eligibility Criteria

Inclusion Criteria: * Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia by bone marrow findings . Age of patients : from 1 year to 50 years. Exclusion Criteria: * \- Other causes of thrombocytopenia as: * Hypersplenism. * Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes. * Cancer treatments like chemotherapy and radiation therapy. * Exposure to toxic chemicals as arsenic and benzene. * Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology